A critical appraisal of the SNAC-K cohort analysis (JAMA Network Open, 2026; n=2,157) reporting that higher meat intake was associated with slower cognitive decline in APOE ε4 carriers but not in non-carriers. Assessed against Bradford Hill criteria, with attention to processed versus unprocessed meat and the limits of observational nutrition evidence.
DHA supplementation in APOE ε4 carriers is stage-dependent. High-dose DHA (≥1–2 g/day) initiated before cognitive decline carries the strongest rationale, while the ADCS trial (Quinn et al., JAMA 2010; n=402) found no benefit in ε4 carriers with established dementia. Molecular form matters: phospholipid-DHA reaches the brain via MFSD2A transport, a route standard triglyceride fish oil does not use.
Distinguishing iNPH from Alzheimer Disease: Key Imaging Differences Neuroimaging · Clinical Differentiation · 2025 Distinguishing iNPH from Alzheimer Disease: Key…
Normal Pressure Hydrocephalus: A Treatable Cause of Dementia-Like Symptoms Evidence-Based Clinical Review · 2025–2026 Normal Pressure Hydrocephalus: The Treatable Dementia…
The Skin-Brain Axis: Dermatological Conditions and Dementia Risk — APOE4 Insights Neurology · Dermatology · Biomarkers The Skin-Brain Axis: What…
An overview of currently approved pharmacotherapy for Alzheimer’s disease — including the anti-amyloid monoclonal antibodies lecanemab and donanemab alongside symptomatic agents — and the genotype-specific considerations affecting candidacy, ARIA risk, and monitoring in APOE ε4 carriers.
Evidence-Based Clinical Review Proactive Diagnostic Evaluation in the APOE ε3/ε4 Heterozygote: A Framework for Midlife Risk Stratification A cognitively healthy…
Amyloid PET Imaging: Mechanism and Clinical Utility in Cognitive Complaints APOE4 Insights · Review · May 2026 Mechanism of Action…
A structured clinical reference on APOE ε4 and cognitive trajectory: genotype-stratified risk estimates, mechanisms of ε4-associated neurodegeneration, and the evidence base for risk-reduction counseling in practice.
Carrying the APOE4 allele is the strongest known genetic risk factor for late-onset Alzheimer’s disease (AD). Research published in Nature…